In particular the recent hypothesis for VEGF‐B as an insulin resistance factor in type II diabetes[16] and its similar importance in NAFLD[18] would indicate the potential for blockade of the VEGF‐B function. This evidence concerns the gene VEGFB and metabolic dysfunction-associated steatotic liver disease.